JP2013245219A5 - - Google Patents

Download PDF

Info

Publication number: JP2013245219A5
Authority: JP; Japan
Prior art keywords: pharmaceutically acceptable; acceptable salt; compound; optionally substituted; aliphatic
Prior art date: 2013-08-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2013169172A

Other languages

English (en)

Japanese (ja)

Other versions

JP2013245219A (ja

JP5706485B2 (ja

Filing date

2013-08-16

Publication date

2014-05-29

2013-08-16 Application filed filed Critical

2013-12-09 Publication of JP2013245219A publication Critical patent/JP2013245219A/ja

2014-05-29 Publication of JP2013245219A5 publication Critical patent/JP2013245219A5/ja

2015-04-22 Application granted granted Critical

2015-04-22 Publication of JP5706485B2 publication Critical patent/JP5706485B2/ja

Status Active legal-status Critical Current

2028-05-09 Anticipated expiration legal-status Critical

Links

150000003839 salts Chemical class 0.000 claims 83
150000001875 compounds Chemical class 0.000 claims 77
125000001931 aliphatic group Chemical group 0.000 claims 29
125000001475 halogen functional group Chemical group 0.000 claims 21
125000004093 cyano group Chemical group *C#N 0.000 claims 17
239000000203 mixture Substances 0.000 claims 13
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 8
229910052739 hydrogen Inorganic materials 0.000 claims 8
229910052799 carbon Inorganic materials 0.000 claims 7
239000001257 hydrogen Substances 0.000 claims 7
108010079245 Cystic Fibrosis Transmembrane Conductance Regulator Proteins 0.000 claims 6
102000008371 intracellularly ATP-gated chloride channel activity proteins Human genes 0.000 claims 6
150000001721 carbon Chemical group 0.000 claims 5
230000000694 effects Effects 0.000 claims 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
125000003107 substituted aryl group Chemical group 0.000 claims 5
102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 4
201000010064 diabetes insipidus Diseases 0.000 claims 4
201000010099 disease Diseases 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
150000002431 hydrogen Chemical class 0.000 claims 4
229920006395 saturated elastomer Polymers 0.000 claims 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
239000012472 biological sample Substances 0.000 claims 3
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 3
239000012634 fragment Substances 0.000 claims 3
125000001072 heteroaryl group Chemical group 0.000 claims 3
208000015439 Lysosomal storage disease Diseases 0.000 claims 2
208000012902 Nervous system disease Diseases 0.000 claims 2
208000025966 Neurological disease Diseases 0.000 claims 2
208000024777 Prion disease Diseases 0.000 claims 2
125000000217 alkyl group Chemical group 0.000 claims 2
125000003118 aryl group Chemical group 0.000 claims 2
230000015271 coagulation Effects 0.000 claims 2
238000005345 coagulation Methods 0.000 claims 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
230000007812 deficiency Effects 0.000 claims 2
230000004064 dysfunction Effects 0.000 claims 2
230000020764 fibrinolysis Effects 0.000 claims 2
125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
150000002632 lipids Chemical class 0.000 claims 2
230000004770 neurodegeneration Effects 0.000 claims 2
208000015122 neurodegenerative disease Diseases 0.000 claims 2
108010040003 polyglutamine Proteins 0.000 claims 2
229920000155 polyglutamine Polymers 0.000 claims 2
125000006413 ring segment Chemical group 0.000 claims 2
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
102100034452 Alternative prion protein Human genes 0.000 claims 1
208000024827 Alzheimer disease Diseases 0.000 claims 1
102000014461 Ataxins Human genes 0.000 claims 1
108010078286 Ataxins Proteins 0.000 claims 1
206010008025 Cerebellar ataxia Diseases 0.000 claims 1
208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
206010062264 Congenital hyperthyroidism Diseases 0.000 claims 1
208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
206010013883 Dwarfism Diseases 0.000 claims 1
206010014561 Emphysema Diseases 0.000 claims 1
208000024720 Fabry Disease Diseases 0.000 claims 1
206010016654 Fibrosis Diseases 0.000 claims 1
201000011240 Frontotemporal dementia Diseases 0.000 claims 1
206010019860 Hereditary angioedema Diseases 0.000 claims 1
208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
206010051125 Hypofibrinogenaemia Diseases 0.000 claims 1
208000000038 Hypoparathyroidism Diseases 0.000 claims 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
208000008955 Mucolipidoses Diseases 0.000 claims 1
206010072928 Mucolipidosis type II Diseases 0.000 claims 1
208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
206010068871 Myotonic dystrophy Diseases 0.000 claims 1
206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
208000018737 Parkinson disease Diseases 0.000 claims 1
102000003992 Peroxidases Human genes 0.000 claims 1
208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
208000026378 Polyglandular endocrine disease Diseases 0.000 claims 1
108091000054 Prion Proteins 0.000 claims 1
201000005660 Protein C Deficiency Diseases 0.000 claims 1
208000021386 Sjogren Syndrome Diseases 0.000 claims 1
208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
208000004622 abetalipoproteinemia Diseases 0.000 claims 1
230000005856 abnormality Effects 0.000 claims 1
125000003545 alkoxy group Chemical group 0.000 claims 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
239000002260 anti-inflammatory agent Substances 0.000 claims 1
229940121363 anti-inflammatory agent Drugs 0.000 claims 1
229960005475 antiinfective agent Drugs 0.000 claims 1
239000004599 antimicrobial Substances 0.000 claims 1
201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 claims 1
230000003115 biocidal effect Effects 0.000 claims 1
229940124630 bronchodilator Drugs 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 claims 1
206010012601 diabetes mellitus Diseases 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
239000003172 expectorant agent Substances 0.000 claims 1
201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
230000004761 fibrosis Effects 0.000 claims 1
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
201000008980 hyperinsulinism Diseases 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
201000001441 melanoma Diseases 0.000 claims 1
208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
229940066491 mucolytics Drugs 0.000 claims 1
206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
230000001272 neurogenic effect Effects 0.000 claims 1
235000016709 nutrition Nutrition 0.000 claims 1
108040007629 peroxidase activity proteins Proteins 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
230000020978 protein processing Effects 0.000 claims 1
210000000463 red nucleus Anatomy 0.000 claims 1
208000002320 spinal muscular atrophy Diseases 0.000 claims 1
125000001424 substituent group Chemical group 0.000 claims 1
208000011580 syndromic disease Diseases 0.000 claims 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
0 C*(C)(*(C1=O)S)N1c1nc(I)cc(C*=N)c1 Chemical compound C*(C)(*(C1=O)S)N1c1nc(I)cc(C*=N)c1 0.000 description 6
JHUBNQSPUZXGKI-UHFFFAOYSA-N CC(C)c(cc1)cc2c1OCO2 Chemical compound CC(C)c(cc1)cc2c1OCO2 JHUBNQSPUZXGKI-UHFFFAOYSA-N 0.000 description 1
KJUMZMXIPUNBFW-UHFFFAOYSA-N Cc1ccc(NC(C2(CC2)c(cc2)cc(O3)c2OC3(F)F)=O)nc1C(C=C1)=CNC1=O Chemical compound Cc1ccc(NC(C2(CC2)c(cc2)cc(O3)c2OC3(F)F)=O)nc1C(C=C1)=CNC1=O KJUMZMXIPUNBFW-UHFFFAOYSA-N 0.000 description 1

JP2013169172A 2007-05-09 2013-08-16 Ｃｆｔｒのモジュレーター Active JP5706485B2 (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US92833407P	2007-05-09	2007-05-09
US60/928,334		2007-05-09

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2010507681A Division JP5497633B2 (ja)	2007-05-09	2008-05-09	Ｃｆｔｒのモジュレーター

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2014084481A Division JP5951674B2 (ja)	2007-05-09	2014-04-16	Ｃｆｔｒのモジュレーター

Publications (3)

Publication Number	Publication Date
JP2013245219A JP2013245219A (ja)	2013-12-09
JP2013245219A5 true JP2013245219A5 (2)	2014-05-29
JP5706485B2 JP5706485B2 (ja)	2015-04-22

Family

ID=39847000

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
JP2010507681A Active JP5497633B2 (ja)	2007-05-09	2008-05-09	Ｃｆｔｒのモジュレーター
JP2013169172A Active JP5706485B2 (ja)	2007-05-09	2013-08-16	Ｃｆｔｒのモジュレーター
JP2014084481A Active JP5951674B2 (ja)	2007-05-09	2014-04-16	Ｃｆｔｒのモジュレーター
JP2015235342A Pending JP2016033162A (ja)	2007-05-09	2015-12-02	Ｃｆｔｒのモジュレーター

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
JP2010507681A Active JP5497633B2 (ja)	2007-05-09	2008-05-09	Ｃｆｔｒのモジュレーター

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
JP2014084481A Active JP5951674B2 (ja)	2007-05-09	2014-04-16	Ｃｆｔｒのモジュレーター
JP2015235342A Pending JP2016033162A (ja)	2007-05-09	2015-12-02	Ｃｆｔｒのモジュレーター

Country Status (8)

Country	Link
US (2)	US8969386B2 (2)
EP (2)	EP2789606B1 (2)
JP (4)	JP5497633B2 (2)
CN (3)	CN102863432B (2)
AU (1)	AU2008251504B2 (2)
CA (1)	CA2686838C (2)
NZ (1)	NZ581259A (2)
WO (1)	WO2008141119A2 (2)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US8969386B2 (en) *	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
EP2639224B1 (en)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
CN102099036B (zh)	2008-06-03	2015-05-27	英特芒尼公司	用于治疗炎性疾患和纤维化疾患的化合物和方法
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
US8415381B2 (en) *	2009-07-30	2013-04-09	Novartis Ag	Heteroaryl compounds and their uses
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
WO2013038378A1 (en) *	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
WO2013038381A1 (en) *	2011-09-16	2013-03-21	Novartis Ag	Pyridine/pyrazine amide derivatives
WO2013038373A1 (en) *	2011-09-16	2013-03-21	Novartis Ag	Pyridine amide derivatives
IN2014KN00885A (2)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
AU2013270681A1 (en)	2012-06-08	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of CFTR -mediated disorders
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP2015530997A (ja) *	2012-08-21	2015-10-29	エフ．ホフマン−ラロシュアーゲーＦ．Ｈｏｆｆｍａｎｎ−ＬａＲｏｃｈｅＡｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ	新規ピリジン誘導体
AR092742A1 (es)	2012-10-02	2015-04-29	Intermune Inc	Piridinonas antifibroticas
ITMI20122065A1 (it)	2012-12-03	2014-06-04	Univ Padova	Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato
SG10201804471PA (en) *	2013-10-18	2018-07-30	Celgene Quanticel Research Inc	Bromodomain inhibitors
JP6963896B2 (ja)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Ｃｆｔｒ媒介性疾患の処置のための医薬組成物を調製する方法
EP2878339A1 (en)	2013-12-02	2015-06-03	Siena Biotech S.p.A.	SIP3 antagonists
WO2015086642A1 (en)	2013-12-13	2015-06-18	F. Hoffmann-La Roche Ag	Inhibitors of bruton's tyrosine kinase
MX382781B (es)	2014-04-02	2025-03-13	Intermune Inc	Piridinonas anti-fibroticas.
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
MX366556B (es)	2014-10-31	2019-07-12	Abbvie Sarl	Cromanos sustituidos y metodo de uso.
PT3221692T (pt)	2014-11-18	2021-09-10	Vertex Pharma	Processo de realização de testagem de alta produtividade por cromatografia líquida de alta eficiência
JP2017178795A (ja) *	2016-03-28	2017-10-05	富士ゼロックス株式会社	化合物、光電変換デバイス、電子写真感光体、プロセスカートリッジ、及び画像形成装置
CN108658851B (zh) *	2017-03-27	2023-06-06	山东特珐曼药业有限公司	2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途
CN112341416A (zh) *	2019-08-09	2021-02-09	天津津艺医药科技发展有限责任公司	一种制备苯并含氧脂杂环衍生物的方法
KR20220161476A (ko) *	2020-04-02	2022-12-06	호라이즌 테라퓨틱스 아일랜드 디에이씨	전신 경화증의 치료 방법
IL298603A (en) *	2020-05-27	2023-01-01	Ariel Prec Medicine Inc	Methods of treating cftr related diseases and disorders
CR20230120A (es)	2020-08-07	2023-09-01	Vertex Pharma	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
CN113881728B (zh) *	2021-09-30	2023-12-15	深圳瑞德林生物技术有限公司	7-氨甲基-7-脱氮鸟嘌呤(PreQ1)的制备方法
US12391640B2 (en)	2022-03-02	2025-08-19	Horizon Therapeutics Ireland Dac	Process of making a crystalline EDG-2 receptor antagonist
WO2024072793A1 (en) *	2022-09-26	2024-04-04	Rectify Pharmaceuticals, Inc.	Pyridine carboxamide compounds and their use in treating medical conditions

Family Cites Families (213)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3758475A (en)	1971-07-20	1973-09-11	Sandoz Ag	Pyrido(2,3-d)pyrimidin 2 ones
IT1226048B (it)	1981-12-14	1990-12-10	Medea Res Srl	Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative
EP0081756B1 (en)	1981-12-14	1985-05-15	MEDEA RESEARCH S.r.l.	New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions
US4501729A (en)	1982-12-13	1985-02-26	Research Corporation	Aerosolized amiloride treatment of retained pulmonary secretions
US5304121A (en)	1990-12-28	1994-04-19	Boston Scientific Corporation	Drug delivery system making use of a hydrogel polymer coating
US5981714A (en)	1990-03-05	1999-11-09	Genzyme Corporation	Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor
JP3167762B2 (ja)	1990-11-27	2001-05-21	武田薬品工業株式会社	ピリドピリダジン誘導体およびその用途
US5612360A (en)	1992-06-03	1997-03-18	Eli Lilly And Company	Angiotensin II antagonists
CA2107196A1 (en)	1992-09-29	1994-03-30	Mitsubishi Chemical Corporation	Carboxamide derivatives
US5886026A (en)	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
GB9317764D0 (en)	1993-08-26	1993-10-13	Pfizer Ltd	Therapeutic compound
KR100342275B1 (ko)	1993-10-21	2002-12-05	지.디. 썰 엘엘씨	산화질소신타제저해제로서유용한아미디노유도체
DE4405712A1 (de)	1994-02-23	1995-08-24	Basf Ag	Substituierte Naphthyridine und deren Verwendung
CZ289317B6 (cs)	1994-04-11	2002-01-16	Sankyo Company Limited	Heterocyklická sloučenina, farmaceutický prostředek ji obsahující a její pouľití
RU2154064C2 (ru)	1994-09-27	2000-08-10	Жансен Фармасетика Н.В.	N-замещенные пиперидинилбензоаты, их n-оксидные формы, фармацевтически приемлемые соли присоединения кислот и стереохимически изомерные формы, способы их получения, фармацевтическая композиция на их основе и промежуточный продукт
US5656256A (en)	1994-12-14	1997-08-12	The University Of North Carolina At Chapel Hill	Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5510379A (en)	1994-12-19	1996-04-23	Warner-Lambert Company	Sulfonate ACAT inhibitors
US6099562A (en)	1996-06-13	2000-08-08	Schneider (Usa) Inc.	Drug coating with topcoat
WO1997036876A1 (en)	1996-04-03	1997-10-09	Merck & Co., Inc.	Inhibitors of farnesyl-protein transferase
AU4159297A (en)	1996-08-23	1998-03-06	Agouron Acquisition Corp.	Neuropeptide-y ligands
CA2276081A1 (en)	1996-12-30	1998-07-09	Lekhanh O. Tran	Inhibitors of farnesyl-protein transferase
US5948814A (en)	1997-02-20	1999-09-07	The Curators Of The University Of Missouri	Genistein for the treatment of cystic fibrosis
WO1998047868A1 (en)	1997-04-18	1998-10-29	Smithkline Beecham Plc	Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists
WO1999018066A1 (en)	1997-10-02	1999-04-15	Sankyo Company, Limited	Amidocarboxylic acid derivatives
ES2216495T3 (es)	1998-02-17	2004-10-16	G.D. SEARLE & CO.	Procedimiento para la resolucion enzimatica de lactamas.
EP1086078B1 (en)	1998-06-08	2003-02-05	Schering Corporation	Neuropeptide y5 receptor antagonists
US6426331B1 (en)	1998-07-08	2002-07-30	Tularik Inc.	Inhibitors of STAT function
AUPP609198A0 (en)	1998-09-22	1998-10-15	Curtin University Of Technology	Use of non-peptidyl compounds for the treatment of insulin related ailments
DE69926806D1 (de)	1998-12-18	2005-09-22	Bristol Myers Squibb Pharma Co	N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren
PT1035115E (pt)	1999-02-24	2005-01-31	Hoffmann La Roche	Derivados de 4-fenilpiridina e a sua utilizacao como antagonistas do receptor nk-1
TR200102490T2 (tr)	1999-02-24	2001-12-21	F.Hoffmann-La Roche Ag	Fenil ve piridinil türevleri
KR100437587B1 (ko)	1999-02-24	2004-06-30	에프. 호프만-라 로슈 아게	3-페닐피리딘 유도체 및 그의 뉴로키닌-1 수용체길항제로서의 용도
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
BR0012291A (pt)	1999-06-18	2002-03-26	Bayer Ag	Fenoxifluorpirimidinas
UA74539C2 (en)	1999-12-08	2006-01-16	Pharmacia Corp	Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
WO2001046165A2 (en)	1999-12-16	2001-06-28	Novartis Ag	N-heteroaryl-amides and their use as parasiticides
EP1248869A2 (en)	2000-01-07	2002-10-16	Transform Pharmaceuticals, Inc.	High-throughput formation, identification, and analysis of diverse solid-forms
WO2001054690A1 (en)	2000-01-28	2001-08-02	Biogen, Inc.	Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses
WO2001056989A2 (en)	2000-02-01	2001-08-09	Cor Therapeutics, Inc.	Inhibitors of factor xa
US20010047100A1 (en)	2000-04-26	2001-11-29	Kjaersgaard Hans Joergen	Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives
WO2001083517A1 (en)	2000-05-03	2001-11-08	Tularik Inc.	Stat4 and stat6 binding dipeptide derivatives
CN1386118A (zh)	2000-06-01	2002-12-18	布里斯托尔-迈尔斯斯奎布药品公司	作为Aβ蛋白产生抑制剂的被环状琥珀酸酯取代的内酰胺类化合物
TWI259180B (en)	2000-08-08	2006-08-01	Hoffmann La Roche	4-Phenyl-pyridine derivatives
WO2002022605A1 (en)	2000-09-15	2002-03-21	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
JP4272338B2 (ja)	2000-09-22	2009-06-03	バイエルアクチェンゲゼルシャフト	ピリジン誘導体
WO2002028348A2 (en)	2000-10-04	2002-04-11	The Children's Hospital Of Philadelphia	Compositions and methods for treatment of cystic fibrosis
GB2367816A (en)	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
ATE269856T1 (de)	2000-10-20	2004-07-15	Merck Patent Gmbh	Chirale binaphtol-verbindungen
US6884782B2 (en)	2000-11-08	2005-04-26	Amgen Inc.	STAT modulators
JP4323802B2 (ja)	2000-12-01	2009-09-02	エムジーアイ・ジーピー・インコーポレーテッド	化合物およびその使用
GB0102687D0 (en)	2001-02-02	2001-03-21	Pharmacia & Upjohn Spa	Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
US6531597B2 (en)	2001-02-13	2003-03-11	Hoffmann-La Roche Inc.	Process for preparation of 2-phenyl acetic acid derivatives
WO2003084997A1 (en)	2001-04-10	2003-10-16	Transtech Pharma, Inc.	Probes, systems and methods for drug discovery
CA2444395C (en)	2001-04-23	2010-12-21	F. Hoffmann-La Roche Ag	Use of nk-1 receptor antagonists against benign prostatic hyperplasia
HUP0400316A2 (hu)	2001-05-22	2005-02-28	Neurogen Corporation	CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények
US20030083345A1 (en)	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
US6627646B2 (en)	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs
WO2003007888A2 (en)	2001-07-20	2003-01-30	Adipogenix, Inc.	Fat accumulation-modulating compounds
CA2448737C (en)	2001-07-20	2010-06-01	Boehringer Ingelheim (Canada) Ltd.	Viral polymerase inhibitors
AU2002333524A1 (en)	2001-09-11	2003-03-24	Glaxosmithkline K.K.	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
PA8557501A1 (es)	2001-11-12	2003-06-30	Pfizer Prod Inc	Benzamida, heteroarilamida y amidas inversas
JP2003155285A (ja)	2001-11-19	2003-05-27	Toray Ind Inc	環状含窒素誘導体
JP2003221386A (ja)	2001-11-26	2003-08-05	Takeda Chem Ind Ltd	二環性誘導体、その製造法およびその用途
PL370989A1 (en)	2001-12-21	2005-06-13	Novo Nordisk A/S	Amide derivatives as gk activators
TW200307539A (en)	2002-02-01	2003-12-16	Bristol Myers Squibb Co	Cycloalkyl inhibitors of potassium channel function
TW200304820A (en)	2002-03-25	2003-10-16	Avanir Pharmaceuticals	Use of benzimidazole analogs in the treatment of cell proliferation
TW200403058A (en)	2002-04-19	2004-03-01	Bristol Myers Squibb Co	Heterocyclo inhibitors of potassium channel function
FR2840807B1 (fr)	2002-06-12	2005-03-11		Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
WO2004035571A1 (en)	2002-10-15	2004-04-29	Rigel Pharmaceuticals, Inc.	Substituted indoles and their use as hcv inhibitors
EP1558576A4 (en)	2002-10-30	2008-04-16	Merck & Co Inc	PIPERIDINYLCYCLOPENTYLARYLBENZYLAMIDE MODULATORS OF CHEMOKIN RECEPTORACTIVITY
MXPA05006367A (es)	2002-12-12	2005-08-29	Pharmacia Corp	Metodo de uso de compuestos de aminocianopiridina como inhibidores de cinasa-2 de proteina activada de cinasa de proteina activada por mitogeno.
DE60336850D1 (en)	2003-01-06	2011-06-01	Lilly Co Eli	Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
RU2351590C2 (ru)	2003-02-10	2009-04-10	Вертекс Фармасьютикалз Инкорпорейтед	Способ получения диариламина
WO2004080972A1 (en)	2003-03-12	2004-09-23	Vertex Pharmaceuticals Incorporated	Pirazole modulators of atp-binding cassette transporters
BRPI0409914A (pt)	2003-04-30	2006-04-25	Inst For Pharm Discovery Inc	ácidos carboxìlicos substituìdos
EP1646615B1 (en)	2003-06-06	2009-08-26	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
GB0315111D0 (en)	2003-06-27	2003-07-30	Cancer Rec Tech Ltd	Substituted 5-membered ring compounds and their use
CA2530075C (en)	2003-06-27	2012-08-21	Harvey Pollard	Amphiphilic pyridinium compounds, method of making and use thereof
JP2005053902A (ja)	2003-07-18	2005-03-03	Nippon Nohyaku Co Ltd	フェニルピリジン類、その中間体及びこれを有効成分とする除草剤
AR045582A1 (es)	2003-09-05	2005-11-02	Neurogen Corp	Piridinas pirazinas y pirimidinas heteroarilo fusionadas como ligandos receptores de crf1
ZA200602755B (en)	2003-09-06	2007-06-27	Vertex Pharma	Modulators of ATP-binding cassette transporters
US7534894B2 (en)	2003-09-25	2009-05-19	Wyeth	Biphenyloxy-acids
US20050070718A1 (en)	2003-09-30	2005-03-31	Abbott Gmbh & Co. Kg	Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
MXPA06004005A (es)	2003-10-08	2006-06-28	Vertex Pharma	Moduladores de transportadores con casete de union con atp.
FR2861304B1 (fr)	2003-10-23	2008-07-18	Univ Grenoble 1	Modulateurs des canaux cftr
GB0325956D0 (en)	2003-11-06	2003-12-10	Addex Pharmaceuticals Sa	Novel compounds
JP4869072B2 (ja)	2003-11-14	2012-02-01	バーテックスファーマシューティカルズインコーポレイテッド	Ａｔｐ結合カセットトランスポーターのモジュレーターとして有用なチアゾールおよびオキサゾール
EP1687001A2 (en)	2003-11-19	2006-08-09	Glaxo Group Limited	Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
MXPA06008606A (es)	2004-01-30	2007-04-13	Vertex Pharma	Moduladores de transportadores con casete de union a atp.
CN100567270C (zh)	2004-02-19	2009-12-09	万有制药株式会社	磺酰胺衍生物
ES2241496B1 (es)	2004-04-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos derivados de piridina.
EP1734820A4 (en)	2004-04-16	2008-01-23	Neurogen Corp	Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands
US7585885B2 (en)	2004-04-22	2009-09-08	Eli Lilly And Company	Pyrrolidine derivatives useful as BACE inhibitors
US7618978B2 (en)	2004-04-22	2009-11-17	Eli Lilly And Company	Amides as BACE inhibitors
CA2568499A1 (en)	2004-06-01	2005-12-15	Tm Bioscience Corporation	Method of detecting cystic fibrosis associated mutations
LT2502911T (lt)	2004-06-24	2017-09-11	Vertex Pharmaceuticals Incorporated	Atp surišančios kasetės transporterių moduliatoriai
US8354427B2 (en)	2004-06-24	2013-01-15	Vertex Pharmaceutical Incorporated	Modulators of ATP-binding cassette transporters
US20140343098A1 (en)	2004-06-24	2014-11-20	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
BRPI0512829A (pt)	2004-07-01	2008-04-08	Warner Lambert Co	preparação de composições farmacêuticas contendo nanopartìculas
CA2572292A1 (en)	2004-07-02	2006-02-09	Advancis Pharmaceutical Corporation	Tablet for pulsed delivery
ZA200700811B (en)	2004-08-06	2008-10-29	Otsuka Pharma Co Ltd	Aromatic compound
EP1794135A1 (en)	2004-09-27	2007-06-13	Amgen Inc.	Substituted heterocyclic compounds and methods of use
BRPI0516093A (pt)	2004-10-12	2008-08-19	Astrazeneca Ab	derivado de quinazolina, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de quinazolina, e, método para tratamento de distúrbios proliferativos celulares em um animal de sanque quente
WO2006051394A1 (en)	2004-11-15	2006-05-18	Pfizer Products Inc.	Azabenzoxazoles for the treatment of cns disorders
CA2589495C (en) *	2004-12-15	2013-10-01	Dompe Pha.R.Ma. S.P.A.	2-arylpropionic acid derivatives and pharmaceutical compositions containing them
JP4790260B2 (ja)	2004-12-22	2011-10-12	出光興産株式会社	アントラセン誘導体を用いた有機エレクトロルミネッセンス素子
WO2006080884A1 (en)	2005-01-27	2006-08-03	Astrazeneca Ab	Novel biaromatic compounds, inhibitors of the p2x7-receptor
US7888374B2 (en)	2005-01-28	2011-02-15	Abbott Laboratories	Inhibitors of c-jun N-terminal kinases
WO2006082952A1 (ja)	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	アミド化合物
EP2363128B1 (en)	2005-03-11	2016-02-17	Vertex Pharmaceuticals Incorporated	Indole modulators of ATP-binding cassette transporters
US7402596B2 (en)	2005-03-24	2008-07-22	Renovis, Inc.	Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
EP1710246A1 (en)	2005-04-08	2006-10-11	Schering Aktiengesellschaft	Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer
TW200716594A (en)	2005-04-18	2007-05-01	Neurogen Corp	Substituted heteroaryl CB1 antagonists
WO2006113919A2 (en)	2005-04-19	2006-10-26	Bayer Pharmaceuticals Corporation	Aryl alkyl acid derivatives for and use thereof
GB0510139D0 (en)	2005-05-18	2005-06-22	Addex Pharmaceuticals Sa	Novel compounds B1
EP1891018B1 (en)	2005-05-24	2011-11-16	Vertex Pharmaceuticals, Inc.	Modulators of atp-binding cassette transporters
JP2008545744A (ja)	2005-06-02	2008-12-18	バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト	フェニルアルキル置換ヘテロアリール誘導体
JP2008543919A (ja)	2005-06-21	2008-12-04	アステックス・セラピューティクス・リミテッド	医薬化合物
ATE512145T1 (de)	2005-08-11	2011-06-15	Vertex Pharma	Modulatoren des cystic fibrosis transmembrane conductance regulators
ES2367844T3 (es)	2005-08-11	2011-11-10	Vertex Pharmaceuticals, Inc.	Moduladores del regulador de la conductancia transmembrana de la fibrosis quística.
EA013909B1 (ru)	2005-09-09	2010-08-30	Смитклайн Бичам Корпорейшн	Пиридиновые производные и их применение для лечения психотических расстройств
CN103893145A (zh)	2005-09-23	2014-07-02	弗·哈夫曼-拉罗切有限公司	新型制剂
AU2006302371A1 (en)	2005-10-06	2007-04-19	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
DK1940821T3 (da)	2005-10-19	2013-06-10	Gruenenthal Gmbh	Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
US20120232059A1 (en)	2005-11-08	2012-09-13	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette Transporters
WO2007054480A1 (en)	2005-11-08	2007-05-18	N.V. Organon	2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor
JP5103403B2 (ja)	2005-12-05	2012-12-19	スミスクラインビーチャムコーポレーション	２−ピリミジニルピラゾロピリジンＥｒｂＢキナーゼ阻害剤
CA2634113A1 (en)	2005-12-24	2007-07-05	Vertex Pharmaceuticals Incorporated	Quinolin- 4 - one derivatives as modulators of abc transporters
AU2006331565A1 (en)	2005-12-27	2007-07-05	Vertex Pharmaceuticals Incorporated	Compounds useful in CFTR assays and methods therewith
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2006336504C9 (en)	2005-12-28	2015-05-14	Vertex Pharmaceuticals Incorporated	1-(benzo [D] [1,3] dioxol-5-yl) -N- (phenyl) cyclopropane- carboxamide derivatives and related compounds as modulators of ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis
US7671221B2 (en)	2005-12-28	2010-03-02	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
NZ571803A (en)	2006-04-07	2011-12-22	Vertex Pharma	Amide indole derivatives as modulators of ATP-binding cassette transporters
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
EP2021797B1 (en)	2006-05-12	2011-11-23	Vertex Pharmaceuticals, Inc.	Compositions of n-ý2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl¨-1,4-dihydro-4-oxoquinoline-3-carboxamide
CA2668305C (en)	2006-11-03	2017-01-03	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as cftr modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
US7754739B2 (en)	2007-05-09	2010-07-13	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
JP2010510974A (ja)	2006-11-27	2010-04-08	ノバルティスアーゲー	置換ジヒドロイミダゾールおよび腫瘍の処置におけるその使用
US20080260820A1 (en)	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
US8969386B2 (en) *	2007-05-09	2015-03-03	Vertex Pharmaceuticals Incorporated	Modulators of CFTR
WO2008147952A1 (en)	2007-05-25	2008-12-04	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20110177999A1 (en)	2007-08-09	2011-07-21	Vertex Pharmaceuticals Incorporated	Therapeutic Combinations Useful in Treating CFTR Related Diseases
HUE028426T2 (en)	2007-08-24	2016-12-28	Vertex Pharma	Isothiazolopyridinones for (inter alia) treating cystic fibrosis
DE102007042754A1 (de)	2007-09-07	2009-03-12	Bayer Healthcare Ag	Substituierte 6-Phenylnikotinsäuren und ihre Verwendung
AU2008298545B2 (en)	2007-09-14	2013-12-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2009038683A2 (en)	2007-09-14	2009-03-26	Vertex Pharmaceuticals Incorporated	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
FR2921657A1 (fr)	2007-09-28	2009-04-03	Sanofi Aventis Sa	Derives de nicotinamide, leur preparation et leur application en therapeutique
SI2217572T1 (sl)	2007-11-16	2014-05-30	Vertex Pharmaceuticals Incorporated	Izokinolinski modulatorji prenaĺ alcev z atp-vezavno kaseto
EP2639224B1 (en)	2007-12-07	2016-08-24	Vertex Pharmaceuticals Incorporated	Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
SI2225230T1 (sl)	2007-12-07	2017-03-31	Vertex Pharmaceuticals Incorporated	Trdne oblike 3-(6-(1-2,2-difluorobenzo(d)(1,3)dioxol-5-il)ciklopropan- karboksamido)-3-metilpiridin-2-il) benzojske kisline
WO2009076141A2 (en)	2007-12-07	2009-06-18	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cycklopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
JP5637859B2 (ja)	2007-12-13	2014-12-10	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	嚢胞性線維症膜コンダクタンスレギュレーターのモジュレーター
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
EP2271621B1 (en)	2008-03-31	2013-11-20	Vertex Pharmaceuticals Incorporated	Pyridyl derivatives as cftr modulators
GB0813709D0 (en)	2008-07-26	2008-09-03	Univ Dundee	Method and product
US20100256184A1 (en)	2008-08-13	2010-10-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
HRP20180328T1 (hr)	2008-08-13	2018-04-20	Vertex Pharmaceuticals Inc.	FARMACEUTSKI PRIPRAVAK N-[2,4-bis(1,1-DIMETILETIL)-5-HIDROKSIFENIL]-1,4-DIHIDRO-4-OKSOKINOLIN-3-KARBOKSAMIDA I NJEGOVO DAVANJE
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
JP2012504143A (ja)	2008-09-29	2012-02-16	バーテックスファーマシューティカルズインコーポレイテッド	３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソール−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の用量単位
NZ592685A (en)	2008-10-23	2013-04-26	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
PT2358680E (pt)	2008-10-23	2013-05-14	Vertex Pharma	Formas sólidas de n-(4-(7-azabiciclo[2.2.1]heptan-7-il)-2- (trifluorometil)fenil)-4-oxo- 5-(trifluorometil)-1,4- dihidroquinolina-3-carboxamida
US8314239B2 (en)	2008-10-23	2012-11-20	Vertex Pharmaceutical Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20110257223A1 (en)	2008-10-23	2011-10-20	Vertex Pharmaceuticals Incorporated	Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
EP2365972B1 (en)	2008-11-06	2014-12-17	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
UA104876C2 (uk)	2008-11-06	2014-03-25	Вертекс Фармасьютікалз Інкорпорейтед	Модулятори atф-зв'язувальних касетних транспортерів
EP2382197B1 (en)	2008-12-30	2016-10-05	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
SI2408750T1 (sl)	2009-03-20	2015-11-30	Vertex Pharmaceuticals Incorporated	Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
HRP20181261T1 (hr)	2009-03-20	2018-12-14	Vertex Pharmaceuticals Incorporated	Modulatori regulatora transmembranske provodljivosti cistične fibroze
EP2427166B1 (en)	2009-05-07	2013-10-16	Gea Pharma Systems Limited	Tablet production module and method for continuous production of tablets
BR112012006031A2 (pt)	2009-09-17	2019-09-24	Vertex Pharma	processo para preparação de compostos azabicíclicos.
US20110098311A1 (en)	2009-10-22	2011-04-28	Vertex Pharmaceuticals Incorported	Compositions for treatment of cystic fibrosis and other chronic diseases
CN102648182A (zh)	2009-10-23	2012-08-22	沃泰克斯药物股份有限公司	用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
WO2011050220A1 (en)	2009-10-23	2011-04-28	Vertex Pharmaceuticals Incorporated	Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
US8471029B2 (en)	2010-03-19	2013-06-25	Vertex Pharmaceutical Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US20110251253A1 (en)	2010-03-25	2011-10-13	Vertex Pharmaceuticals Incorporated	Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
HRP20160682T1 (hr)	2010-04-07	2016-07-29	Vertex Pharmaceuticals Incorporated	Čvrsti oblici 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksiamido)-3-metilpiridin-2-il)benzojeve kiseline
HRP20211752T1 (hr)	2010-04-07	2022-02-18	Vertex Pharmaceuticals Incorporated	Farmaceutski pripravci 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzojeve kiseline i njihova primjena
CA2796642A1 (en)	2010-04-22	2011-10-27	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
AU2011242454A1 (en)	2010-04-22	2012-11-08	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
ES2608474T3 (es)	2010-04-22	2017-04-11	Vertex Pharmaceuticals Incorporated	Proceso de producción de compuestos indol cycloalkylcarboxamido
NZ603044A (en)	2010-04-22	2015-08-28	Vertex Pharma	Pharmaceutical compositions comprising cftr modulators and administrations thereof
TW201202250A (en)	2010-05-20	2012-01-16	Vertex Pharma	Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
CA2798412A1 (en)	2010-05-20	2011-11-24	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions and administrations thereof
US8563593B2 (en)	2010-06-08	2013-10-22	Vertex Pharmaceuticals Incorporated	Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
CA2808501A1 (en)	2010-08-23	2012-03-01	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof
RU2013113627A (ru)	2010-08-27	2014-10-10	Вертекс Фармасьютикалз Инкорпорейтед	Фармацевтическая композиция и ее введения
EP2452972B2 (de)	2010-11-10	2022-04-13	Continental Reifen Deutschland GmbH	Nutzfahrzeugluftreifen
US8802700B2 (en)	2010-12-10	2014-08-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
EP2773349A1 (en)	2011-11-02	2014-09-10	Vertex Pharmaceuticals Incorporated	Use of (n- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl]- 1, 4 - dihydro - 4 - oxoquinoline - 3 - carboxamide) for treating cftr mediated diseases
US20140127901A1 (en)	2012-11-08	2014-05-08	Taiwan Semiconductor Manufacturing Company, Ltd.	Low-k damage free integration scheme for copper interconnects
IN2014KN00885A (2)	2011-11-08	2015-10-02	Vertex Pharma
WO2013112804A1 (en)	2012-01-25	2013-08-01	Vertex Pharmaceuticals Incorporated	Formulations of 3-(6-(1-(2.2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
EP2819670A1 (en)	2012-02-27	2015-01-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administration thereof
US8674108B2 (en)	2012-04-20	2014-03-18	Vertex Pharmaceuticals Incorporated	Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
AU2013270681A1 (en)	2012-06-08	2014-12-18	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for the treatment of CFTR -mediated disorders
WO2014014841A1 (en)	2012-07-16	2014-01-23	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
LT3470063T (lt)	2012-11-02	2025-02-10	Vertex Pharmaceuticals Incorporated	Farmacinės kompozicijos, skirtos cftr nulemtų ligų gydymui
US20140221424A1 (en)	2013-01-30	2014-08-07	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions for use in the treatment of cystic fibrosis
ES2885181T3 (es)	2014-04-15	2021-12-13	Vertex Pharma	Composiciones farmacéuticas para el tratamiento de enfermedades mediadas por el regulador de la conductancia transmembrana de fibrosis quística
TWI735416B (zh)	2014-10-06	2021-08-11	美商維泰克斯製藥公司	囊腫纖維化症跨膜傳導調節蛋白之調節劑
KR20170063954A (ko)	2014-10-07	2017-06-08	버텍스 파마슈티칼스 인코포레이티드	낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
WO2016086136A1 (en)	2014-11-26	2016-06-02	Catabasis Pharmaceuticals, Inc.	Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
MA41031A (fr)	2014-11-26	2017-10-03	Catabasis Pharmaceuticals Inc	Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
US10414768B2 (en)	2014-12-05	2019-09-17	Centre National De La Recherche Scientifique (Cnrs)	Compounds for treating cystic fibrosis
JP6662885B2 (ja)	2015-01-26	2020-03-11	ライジェルファーマシューティカルズ，インコーポレイテッド	カルボン酸生物学的等価体としてのテトラゾロン
TWI730959B (zh)	2015-05-19	2021-06-21	英商葛蘭素史克智慧財產發展有限公司	作為激酶抑制劑之雜環醯胺

2008
- 2008-05-09 US US12/117,941 patent/US8969386B2/en active Active
- 2008-05-09 NZ NZ581259A patent/NZ581259A/xx unknown
- 2008-05-09 AU AU2008251504A patent/AU2008251504B2/en active Active
- 2008-05-09 CA CA2686838A patent/CA2686838C/en active Active
- 2008-05-09 EP EP14168373.0A patent/EP2789606B1/en active Active
- 2008-05-09 CN CN201210355068.2A patent/CN102863432B/zh active Active
- 2008-05-09 CN CN201410752029.5A patent/CN104447716A/zh active Pending
- 2008-05-09 WO PCT/US2008/063144 patent/WO2008141119A2/en not_active Ceased
- 2008-05-09 JP JP2010507681A patent/JP5497633B2/ja active Active
- 2008-05-09 EP EP08769357A patent/EP2164840A2/en not_active Withdrawn
- 2008-05-09 CN CN2008800226231A patent/CN101687842B/zh active Active
2013
- 2013-08-16 JP JP2013169172A patent/JP5706485B2/ja active Active
2014
- 2014-04-16 JP JP2014084481A patent/JP5951674B2/ja active Active
2015
- 2015-02-27 US US14/633,278 patent/US9725440B2/en active Active
- 2015-12-02 JP JP2015235342A patent/JP2016033162A/ja active Pending

Publication	Publication Date	Title
JP2013245219A5 (2)	2014-05-29
JP2010526831A5 (2)	2012-06-07
JP2012514038A5 (2)	2013-02-07
JP2011513321A5 (2)	2013-03-07
JP2010539185A5 (2)	2012-10-25
JP2007519740A5 (2)	2008-02-28
JP2010528050A5 (2)	2012-07-05
JP2011505338A5 (2)	2012-12-06
JP2009521468A5 (2)	2011-02-17
JP2011506474A5 (2)	2013-02-07
JP2007509044A5 (2)	2007-11-22
JP2012521362A5 (2)	2013-04-25
JP2019513741A5 (2)	2020-05-14
RU2010114732A (ru)	2011-10-20	Твердые формы n-[2,4-бис(1,1-диметилэтил)-5-гидроксифенил]-1,4-дигидро-4-оксохинолин-3-карбоксамида
JP6521967B2 (ja)	2019-05-29	疾患の治療のためのｋｄｍ１ａ阻害剤
JP2012521361A5 (2)	2013-05-02
JP2021524838A5 (2)	2022-06-01
JP2009522277A5 (2)	2010-02-18
HRP20170847T1 (hr)	2017-08-25	Modulatori atp - vezujućih kasetnih transportera
JP6034861B2 (ja)	2016-11-30	ジュウテリウム富化４−ヒドロキシ−５−メトキシ−ｎ，１−ジメチル−２−オキソ−ｎ−［（４−トリフルオロ−メチル）フェニル］−１，２−ジヒドロキノリン−３−カルボキサミド
JP2013508407A5 (2)	2013-12-05
SI3091011T1 (en)	2018-06-29	Modulators of ATP conveyor belt conveyors
MY165906A (en)	2018-05-18	Phenothiazine diaminium salts and their use
RU2017126232A (ru)	2019-01-29	Соединения, композиции и способы для повышения активности cftr
RU2011120327A (ru)	2012-11-27	Твердые формы n-(4-(7-азабицикло[2.2.1]гептан-7-ил-)-2-(трифторметил)фенил)-4-оксо-5-(трифторметил)-1,4-дигидрохинолин-3-карбоксамида